ES2542853T3 - Método para tratar miastenia grave - Google Patents

Método para tratar miastenia grave Download PDF

Info

Publication number
ES2542853T3
ES2542853T3 ES06779285.3T ES06779285T ES2542853T3 ES 2542853 T3 ES2542853 T3 ES 2542853T3 ES 06779285 T ES06779285 T ES 06779285T ES 2542853 T3 ES2542853 T3 ES 2542853T3
Authority
ES
Spain
Prior art keywords
protein
myasthenia gravis
complement
homologue
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06779285.3T
Other languages
English (en)
Inventor
John Hamer
Wynne Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Application granted granted Critical
Publication of ES2542853T3 publication Critical patent/ES2542853T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/16—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans
    • A61B17/1604—Chisels; Rongeurs; Punches; Stamps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/46—Special tools for implanting artificial joints
    • A61F2/4603—Special tools for implanting artificial joints for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/16—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans
    • A61B17/1613—Component parts
    • A61B17/1631—Special drive shafts, e.g. flexible shafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/16—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans
    • A61B17/1662—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans for particular parts of the body
    • A61B17/1671—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans for particular parts of the body for the spine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/46—Special tools for implanting artificial joints
    • A61F2/4603—Special tools for implanting artificial joints for insertion or extraction of endoprosthetic joints or of accessories thereof
    • A61F2/4611—Special tools for implanting artificial joints for insertion or extraction of endoprosthetic joints or of accessories thereof of spinal prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/16—Instruments for performing osteoclasis; Drills or chisels for bones; Trepans
    • A61B17/1613—Component parts
    • A61B17/1633—Sleeves, i.e. non-rotating parts surrounding the bit shaft, e.g. the sleeve forming a single unit with the bit shaft

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)

Abstract

Un agente derivado de un artrópodo hematófago que se une al complemento C5 para su uso en el tratamiento o prevención de miastenia grave, en el que el agente que se une al complemento C5 es: (a) una proteína que comprende o que consiste en los aminoácidos 19 a 168 de la secuencia de aminoácidos de SEC ID Nº: 2; (b) una proteína que comprende o que consiste en los aminoácidos 1 a 168 de la secuencia de aminoácidos de SEC ID Nº: 2; (c) un homólogo que tiene más del 60 % de identidad de secuencias con la proteína como se define en (a) o (b); o (d) un fragmento de la proteína como se define en (a) o (b) o de un homólogo como se define en (c), en el que dicho fragmento retiene la capacidad para unirse al complemento C5.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
    imagen2
ES06779285.3T 2005-09-09 2006-09-05 Método para tratar miastenia grave Active ES2542853T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0518443.7A GB0518443D0 (en) 2005-09-09 2005-09-09 Method of treating myasthenia gravis
GB0518443 2005-09-09
PCT/GB2006/003265 WO2007028968A1 (en) 2005-09-09 2006-09-05 Method of treating myasthenia gravis

Publications (1)

Publication Number Publication Date
ES2542853T3 true ES2542853T3 (es) 2015-08-12

Family

ID=35221219

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06779285.3T Active ES2542853T3 (es) 2005-09-09 2006-09-05 Método para tratar miastenia grave

Country Status (11)

Country Link
US (3) US9192648B2 (es)
EP (2) EP1931372B1 (es)
JP (1) JP5254792B2 (es)
CN (3) CN103505721A (es)
AU (1) AU2006288985B2 (es)
CA (1) CA2621697C (es)
DK (1) DK1931372T3 (es)
ES (1) ES2542853T3 (es)
GB (1) GB0518443D0 (es)
NZ (1) NZ566789A (es)
WO (2) WO2007028968A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
HUE061548T2 (hu) * 2008-11-10 2023-07-28 Alexion Pharma Inc Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
US10039802B2 (en) * 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
AU2014314214C1 (en) 2013-08-28 2019-01-24 Affibody Ab Binding polypeptides having a mutated scaffold
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN119950719A (zh) * 2016-05-13 2025-05-09 德尔诺瓦股份有限公司 化学去神经化所致的副作用的治疗
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
WO2018140412A1 (en) * 2017-01-24 2018-08-02 Gt Biopharma, Inc. Neostigmine combination and compositions
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2019023175A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
CN120571008A (zh) 2017-12-13 2025-09-02 瑞泽恩制药公司 抗c5抗体组合及其用途
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
WO2024039740A2 (en) * 2022-08-16 2024-02-22 Gro Biosciences Inc. Polypeptide compositions containing non-standard glycan stub amino acids and methods of making and uses thereof
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041389A (en) * 1986-01-06 1991-08-20 The Salk Institute For Biological Studies Assays for myasthenia gravis
WO1993017099A1 (en) 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US5339801A (en) * 1992-03-12 1994-08-23 Uresil Corporation Surgical retractor and surgical method
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
US20080199484A1 (en) * 2003-10-06 2008-08-21 Cedars-Sinai Medical Center Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
HUE050481T2 (hu) * 2004-02-12 2020-12-28 Archemix Llc Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
JP2009533428A (ja) 2006-04-12 2009-09-17 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 筋肉内抗ウイルス処置
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
EP2236100B1 (en) * 2009-03-30 2017-06-28 Arthrex, Inc. Microfracture instrument
US20130072936A1 (en) * 2009-11-10 2013-03-21 John To Angled grinder
US8840668B1 (en) * 2009-11-11 2014-09-23 Nuvasive, Inc. Spinal implants, instruments and related methods
US8740983B1 (en) 2009-11-11 2014-06-03 Nuvasive, Inc. Spinal fusion implants and related methods
US8562592B2 (en) * 2010-05-07 2013-10-22 Ethicon Endo-Surgery, Inc. Compound angle laparoscopic methods and devices
US20120071876A1 (en) * 2010-09-17 2012-03-22 Stoll E Jordan Microfracture awl
US20120185045A1 (en) * 2011-01-14 2012-07-19 Zimmer Spine, Inc. Articulating spinal implant insertion instrument
US9386999B2 (en) * 2013-03-13 2016-07-12 Depuy (Ireland) Tibial orthopaedic surgical instruments for setting offset
WO2015020956A1 (en) * 2013-08-05 2015-02-12 Blumenthal Scott L Vertebral endplate apparatus and method
EP3035859B1 (en) * 2013-08-23 2018-04-04 Covidien LP Specimen retrieval device
US10172650B2 (en) * 2014-10-21 2019-01-08 Warsaw Orthopedic, Inc. Spinal implant system and method
US10265194B2 (en) * 2015-04-01 2019-04-23 Zimmer Biomet Spine, Inc. Insertion instrument with articulating wrist
US10004609B2 (en) * 2016-09-23 2018-06-26 Warsaw Orthopedic, Inc. Surgical instrument and method

Also Published As

Publication number Publication date
DK1931372T3 (en) 2015-05-26
EP1931372A1 (en) 2008-06-18
WO2007028968A1 (en) 2007-03-15
CN114555013A (zh) 2022-05-27
AU2006288985B2 (en) 2011-09-29
CN114555013B (zh) 2026-02-17
JP5254792B2 (ja) 2013-08-07
WO2007028968A9 (en) 2008-06-12
WO2021080910A1 (en) 2021-04-29
EP4048171A1 (en) 2022-08-31
US20200282018A1 (en) 2020-09-10
NZ566789A (en) 2011-11-25
US20160166640A1 (en) 2016-06-16
US9192648B2 (en) 2015-11-24
AU2006288985A1 (en) 2007-03-15
CA2621697A1 (en) 2007-03-15
GB0518443D0 (en) 2005-10-19
CA2621697C (en) 2017-08-29
CN101340926A (zh) 2009-01-07
EP4048171A4 (en) 2023-11-22
EP1931372B1 (en) 2015-04-29
US20090209459A1 (en) 2009-08-20
JP2009508819A (ja) 2009-03-05
CN103505721A (zh) 2014-01-15

Similar Documents

Publication Publication Date Title
ES2542853T3 (es) Método para tratar miastenia grave
ES2528133T3 (es) Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
CO2022003582A2 (es) Métodos para el tratamiento de la oftalmopatía tiroidea
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
CO6700829A2 (es) Moduladores novedosos y métodos de uso
AR083293A1 (es) Agentes de union a cd33
NO20063026L (no) Antistoffer
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
AR086510A2 (es) Agentes de union especifica al factor de crecimiento de hepatocitos
UY33034A (es) Materiales y métodos para el tratamiento o prevención de enfermedades asociadas al her-3
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
ES2539790T3 (es) Métodos y composiciones para modular c-met hiperestabilizado
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
PE20140673A1 (es) Nuevos moduladores y metodos para su uso